Acute fulminant hepatitis associated with osimertinib administration in a lung cancer patient with chronic hepatitis B: The first mortality case report

Osimertinib is the most efficient first‐line drug, with least adverse effects, for metastatic non‐small‐cell lung carcinoma (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations with exon 19 deletion or exon 21 L858R mutations. Herein, we present a 68‐year‐old woman who had chronic hep...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, You‐Kuang, Meng, Fan‐Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977162/
https://www.ncbi.nlm.nih.gov/pubmed/35146920
http://dx.doi.org/10.1111/1759-7714.14346
_version_ 1784680709823135744
author Kang, You‐Kuang
Meng, Fan‐Chun
author_facet Kang, You‐Kuang
Meng, Fan‐Chun
author_sort Kang, You‐Kuang
collection PubMed
description Osimertinib is the most efficient first‐line drug, with least adverse effects, for metastatic non‐small‐cell lung carcinoma (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations with exon 19 deletion or exon 21 L858R mutations. Herein, we present a 68‐year‐old woman who had chronic hepatitis B with aggressive NSCLC and received osimertinib as cancer treatment for 4.5 months. This is the first report of mortality due to osimertinib‐related acute fulminant hepatitis. Clinicians should routinely arrange for hepatitis B virus (HBV) screening and prescribe antiviral drugs to patients with chronic HBV infection before osimertinib administration.
format Online
Article
Text
id pubmed-8977162
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-89771622022-04-05 Acute fulminant hepatitis associated with osimertinib administration in a lung cancer patient with chronic hepatitis B: The first mortality case report Kang, You‐Kuang Meng, Fan‐Chun Thorac Cancer Case Reports Osimertinib is the most efficient first‐line drug, with least adverse effects, for metastatic non‐small‐cell lung carcinoma (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations with exon 19 deletion or exon 21 L858R mutations. Herein, we present a 68‐year‐old woman who had chronic hepatitis B with aggressive NSCLC and received osimertinib as cancer treatment for 4.5 months. This is the first report of mortality due to osimertinib‐related acute fulminant hepatitis. Clinicians should routinely arrange for hepatitis B virus (HBV) screening and prescribe antiviral drugs to patients with chronic HBV infection before osimertinib administration. John Wiley & Sons Australia, Ltd 2022-02-11 2022-04 /pmc/articles/PMC8977162/ /pubmed/35146920 http://dx.doi.org/10.1111/1759-7714.14346 Text en © 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Kang, You‐Kuang
Meng, Fan‐Chun
Acute fulminant hepatitis associated with osimertinib administration in a lung cancer patient with chronic hepatitis B: The first mortality case report
title Acute fulminant hepatitis associated with osimertinib administration in a lung cancer patient with chronic hepatitis B: The first mortality case report
title_full Acute fulminant hepatitis associated with osimertinib administration in a lung cancer patient with chronic hepatitis B: The first mortality case report
title_fullStr Acute fulminant hepatitis associated with osimertinib administration in a lung cancer patient with chronic hepatitis B: The first mortality case report
title_full_unstemmed Acute fulminant hepatitis associated with osimertinib administration in a lung cancer patient with chronic hepatitis B: The first mortality case report
title_short Acute fulminant hepatitis associated with osimertinib administration in a lung cancer patient with chronic hepatitis B: The first mortality case report
title_sort acute fulminant hepatitis associated with osimertinib administration in a lung cancer patient with chronic hepatitis b: the first mortality case report
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977162/
https://www.ncbi.nlm.nih.gov/pubmed/35146920
http://dx.doi.org/10.1111/1759-7714.14346
work_keys_str_mv AT kangyoukuang acutefulminanthepatitisassociatedwithosimertinibadministrationinalungcancerpatientwithchronichepatitisbthefirstmortalitycasereport
AT mengfanchun acutefulminanthepatitisassociatedwithosimertinibadministrationinalungcancerpatientwithchronichepatitisbthefirstmortalitycasereport

Ejemplares similares